AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback